As GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs ...

The S&P 500 climbed roughly 3% to a record close and its first all-time high since February. The Nasdaq Composite rose about 4%, also hitting a fresh record, as investors continued to pile into ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

“The benefits people report most often are way more energy, better workouts and faster recovery, higher libido, clearer ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Analysts are intrested in these 5 stocks: ( ($SMR) ), ( ($HIMS) ), ( ($SNOW) ), ( ($AAP) ) and ( ($EXEL) ). Here is a breakdown of their recent ...

Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

The purpose of this pilgrimage was to celebrate the jubilee year of hope. It is also Hope House Ministries’ 45th anniversary.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...